spacer
home > ebr > autumn 2009 > peptide potential
PUBLICATIONS
European Biopharmaceutical Review

Peptide Potential

 

Peptides, the most basic of building blocks in physiology, continue to grow in prominence among pharmaceutical manufacturers. With inherent abilities to block or enhance signal transfers in the human body, peptides, when harnessed as active pharmaceutical ingredients, can treat a host of metabolic diseases, cardiovascular and heart conditions, and neurodegenerative disorders.

Peptide-based drug targets are being identified at an increasingly rapid pace, both in terms of recently introduced therapies, and products in the development pipeline. In fact, a recent report by market and technology research firm Frost & Sullivan indicated that more than 40 approved peptide-based drugs are in use today, and approximately 400 are being developed to treat allergies, cancer, Alzheimerís, Huntingtonís and Parkinsonís diseases (1).

Peptide-based therapies tap into the direct hardwiring of human physiology, yielding substantial and far-reaching benefits to drug treatments and therapies. Moreover, developments in peptide manufacturing and implementation have made these amino acid compounds more accessible to the market in terms of cost, flexibility and effectiveness.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Hu oversees all non-GMP and GMP business divisions within the American Peptide Company (APC). He has been with APC for 18 years and he is tasked with keeping the organisation profitable and meeting growth objectives year after year. Gary spearheads the Total Peptide ManagementTM programme, a flagship initiative designed to help the pharmaceutical and life sciences industries bring new and innovative drugs to market faster. Specialising in business development, he emphasises a team approach to bring value and integrity to customersí projects.
spacer
Gary Hu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Protagen Protein Services (PPS) expands capabilities for aggregate analytics to include dynamic light scattering (DLS)

Protein aggregation is a common challenge in the manufacturing of biological products. As one of the most sensitive techniques for the detection of aggregates, dynamic light scattering (DLS) provides a simple, fast and non-destructive testing method. An innovative technique based on a unique cuvette layout allows for accurate measurements with as little as a single ĶL of solution.
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement